By Bruce Japsen | The looming decline in sales from the blockbuster diabetes drug Actos
figured into Takeda Pharmaceutical Co.’s decision Wednesday to slash
nearly 1,600 U.S. jobs — including hundreds in Chicago’s northern
suburbs.
Japan’s largest drug maker operates from its U.S. base in Deerfield
under the name Takeda Pharmaceuticals North America Inc. It faces
competition in the next two years from upcoming generic versions of its
flagship product, the diabetes prescription Actos.